Recent developments in the perioperative management of adult patients with chronic kidney disease

British Journal of Anaesthesia

Volumn 101, Issue 3, 2008, Pages 296-310

  Craig, R G ^a   Hunter, J M ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Anaesthesia, general; Blood, coagulation; Cardiovascular system, effects; Kidney, failure

Indexed keywords

ANESTHESIST; CHRONIC KIDNEY DISEASE; FLUID BALANCE; HUMAN; PATHOPHYSIOLOGY; PEROPERATIVE CARE; PRIORITY JOURNAL; REVIEW; VASCULAR ACCESS; ADULT; CHRONIC KIDNEY FAILURE; GENERAL ANESTHESIA; METABOLISM; METHODOLOGY; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION;

ANALGESIC AGENT; ANESTHETIC AGENT;

ADULT; ANALGESICS; ANESTHESIA, GENERAL; ANESTHETICS; HUMANS; KIDNEY FAILURE, CHRONIC; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS;

EID: 50949094641     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aen203     Document Type: Review

References (149)

1. Akman B, Afsar B, Atac FB, et al. Predictors of vascular access thrombosis among patients on the cadaveric renal transplantation waiting list. Transplant Proc 2006; 38: 413-415
2. Alimchandani A, Pai-dhungat JV. A study of gastric emptying in chronic renal failure. J Assoc Physicians India 1997; 45: 835-838
3. Ansell D, Feest TG, Tomson C, Williams AJ, Warwick G. UK Renal Registry Report 2006. Bristol, UK: UK Renal Registry, 2007
4. Barr GA, Cousins MJ, Mazze RI, Hitt BA, Kosek JC. A comparison of the renal effects and metabolism of enflurane and methoxyflurane in Fischer 344 rats. J Pharmacol Exp Ther 1974; 188: 257-264
5. Bastani B, Jamal JA. Removal of morphine but not fentanyl during haemodialysis. Nephrol Dial Transplant 1997; 12: 2802-2804
6. Bencini AF, Scaf AH, Sohn YJ, et al. Disposition and urinary excretion of vecuronium bromide in anesthetized patients with normal renal function or renal failure. Anesth Analg 1986; 65: 245-251
7. Berg KJ, Djoseland O, Gjellan A, et al. Acute effects of paracetamol on prostaglandin synthesis and renal function in normal man and in patients with renal failure. Clin Nephrol 1990; 34: 255-262
8. Bevan DR, Donati F, Gyasi H, Williams A. Vecuronium in renal failure. Can Anaesth Soc J 1984; 31: 491-496
9. Blain PG, Lane RJ, Bateman DN, Rawlins MD. Opiate-induced rhabdomyolysis. Hum Toxicol 1985; 4: 71-74
10. Bondia A, Tabernero JM, Macias JF, Martin-Luengo C. Autonomic nervous system in haemodialysis. Nephrol Dial Transplant 1988; 3: 174-180
11. Bower S, Sear JW. Disposition of alfentanil in patients receiving a renal transplant. J Pharm Pharmacol 1989; 41: 654-657 (Pubitemid 19256618)
12. Boyd AH, Eastwood NB, Parker CJ, Hunter JM. Pharmacodynamics of the 1R cis-10R cis isomer of atracurium (51W89) in health and chronic renal failure. Br J Anaesth 1995; 74: 400-404
13. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358: 125-139
14. Burch PG, Stanski DR. Decreased protein binding and thiopental kinetics. Clin Pharmacol Ther 1982; 32: 212-217
15. Calvo C, Maule S, Mecca F, Quadri R, Martina G, Cavallo PP. The influence of autonomic neuropathy on hypotension during hemodialysis. Clin Auton Res 2002; 12: 84-87
16. Chapple DJ, Miller AA, Ward JB, Wheatley PL. Cardiovascular and neurological effects of laudanosine. Studies in mice and rats, and in conscious and anaesthetized dogs. Br J Anaesth 1987; 59: 218-225
17. Chauvin M, Lebrault C, Levron JC, Duvaldestin P. Pharmacokinetics of alfentanil in chronic renal failure. Anesth Analg 1987; 66: 53-56
18. Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P. Morphine pharmacokinetics in renal failure. Anesthesiology 1987; 66: 327-331
19. Christensen JH, Andreasen F, Jansen J. Pharmacokinetics and pharmacodynamics of thiopental in patients undergoing renal transplantation. Acta Anaesthesiol Scand 1983; 27: 513-518
20. Cimochowski GE, Worley E, Rutherford WE, Sartain J, Blondin J, Harter H. Superiority of the internal jugular over the subclavian access for temporary dialysis. Nephron 1990; 54: 154-161
21. Cirella VN, Pantuck CB, Lee YJ, Pantuck EJ. Effects of cyclosporine on anesthetic action. Anesth Analg 1987; 66: 703-706
22. Cittanova ML, Leblanc I, Legendre C, Mouquet C, Riou B, Coriat P. Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 1996; 348: 1620-1622
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
24. Conzen PF, Nuscheler M, Melotte A, et al. Renal function and serum fluoride concentrations in patients with stable renal insufficiency after anesthesia with sevoflurane or enflurane. Anesth Analg 1995; 81: 569-575
25. Cooper RA, Maddineni VR, Mirakhur RK, Wierda JM, Brady M, Fitzpatrick KT. Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. Br J Anaesth 1993; 71: 222-226
26. Cosimi AB, Jenkins RL, Rohrer RJ, Delmonico FL, Hoffman M, Monaco AP. A randomized clinical trial of prophylactic OKT3 monoclonal antibody in liver allograft recipients. Arch Surg 1990; 125: 781-784
27. Costela JL, Jimenez R, Calvo R, Suarez E, Carlos R. Serum protein binding of propofol in patients with renal failure or hepatic cirrhosis. Acta Anaesthesiol Scand 1996; 40: 741-745
28. Cousins MJ, Mazze RI, Kosek JC, Hitt BA, Love FV. The etiology of methoxyflurane nephrotoxicity. J Pharmacol Exp Ther 1974; 190: 530-541
29. Dahaba AA, Von Klobucar F, Rehak PH, List WF. Total intravenous anesthesia with remifentanil, propofol and cisatracurium in end-stage renal failure. Can J Anaesth 1999; 46: 696-700
30. Dahaba AA, Oettl K, Von Klobucar F, Reibnegger G, List WF. End-stage renal failure reduces central clearance and prolongs the elimination half life of remifentanil. Can J Anaesth 2002; 49: 369-374
31. Dauri M, Costa F, Servetti S, Sidiropoulou T, Fabbi E, Sabato AF. Combined general and epidural anesthesia with ropivacaine for renal transplantation. Minerva Anestesiol 2003; 69: 873-884
32. Dhingra RK, Young EW, Hulbert-Shearon TE, Leavey SF, Port FK. Type of vascular access and mortality in U.S. hemodialysis patients. Kidney Int 2001; 60: 1443-1451
33. Duthie DJR. Renal failure, surgery and fentanyl pharmacokinetics. Abstracts of VII European Congress of Anaesthesiology, volume I. Beitrage zur Anaesthesiologie und Intensivmedizin 1986; 16: 187
34. Eastwood NB, Boyd AH, Parker CJ, Hunter JM. Pharmacokinetics of 1R-cis 1'R-cis atracurium besylate (51W89) and plasma laudanosine concentrations in health and chronic renal failure. Br J Anaesth 1995; 75: 431-435
35. Eichhorn JH, Hedley-Whyte J, Steinman TI, Kaufmann JM, Laasbert LH. Renal failure following enflurane anesthesia. Anesthesiology 1976; 45: 557-560
36. Elston AC, Bayliss MK, Park GR. Effect of renal failure on drug metabolism by the liver. Br J Anaesth 1993; 71: 282-290
37. Ewing DJ, Clarke BF. Diagnosis and management of diabetic autonomic neuropathy. Br Med J (Clin Res Ed) 1982; 285: 916-918
38. Fahey MR, Rupp SM, Fisher DM, et al. The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure. Anesthesiology 1984; 61: 699-702
39. Falk A, Prabhuram N, Parthasarathy S. Conversion of temporary hemodialysis catheters to permanent hemodialysis catheters: a retrospective study of catheter exchange versus classic de novo placement. Semin Dial 2005; 18: 425-430
40. Fernandez F, Goudable C, Sie P, et al. Low haematocrit and prolonged bleeding time in uraemic patients: effect of red cell transfusions. Br J Haematol 1985; 59: 139-148
41. Ferrari F, Nascimento P Jr, Vianna PT. Complete atrioventricular block during renal transplantation in a patient with Alport's syndrome: case report. Sao Paulo Med J 2001; 119: 184-186
42. First MR. Improving long-term renal transplant outcomes with tacrolimus: speculation vs evidence. Nephrol Dial Transplant 2004; 19: vi17-22
43. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 2007; 116: e418-99
44. Gardner JS, Blough D, Drinkard CR, et al. Tramadol and seizures: a surveillance study in a managed care population. Pharmacotherapy 2000; 20: 1423-1431
45. Gaston RS. Maintenance immunosuppression in the renal transplant recipient: an overview. Am J Kidney Dis 2001; 38: S25-35
46. George J, Aron A, Levy Y, et al. Anti-cardiolipin, antiendothelial- cell and anti-malondialdehyde-LDL antibodies in uremic patients undergoing hemodialysis: relationship with vascular access thrombosis and thromboembolic events. Hum Antibodies 1999; 9: 125-131
47. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin- Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med 1997; 127: 337-345
48. Gonsowski CT, Laster MJ, Eger EI, Ferrell LD, Kerschmann RL. Toxicity of compound A in rats. Effect of increasing duration of administration. Anesthesiology 1994; 80: 566-573
49. Goyal P, Puri GD, Pandey CK, Srivastva S. Evaluation of induction doses of propofol: comparison between endstage renal disease and normal renal function patients. Anaesth Intensive Care 2002; 30: 584-587
50. Gramstad L. Atracurium, vecuronium and pancuronium in endstage renal failure. Dose-response properties and interactions with azathioprine. Br J Anaesth 1987; 59: 995-1003
51. Guay DR, Awni WM, Findlay JW, et al. Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. Clin Pharmacol Ther 1988; 43: 63-71
52. Gultekin F, Alagozlu H, Candan F, Nadir I, Bakici MZ, Sezer H. The relationship between anticardiolipin antibodies and vascular access occlusion in patients on hemodialysis. ASAIO J 2005; 51: 162-164
53. Hallan S, Asberg A, Lindberg M, Johnsen H. Validation of the modification of diet in renal disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. Am J Kidney Dis 2004; 44: 84-93
54. Hamad A, Salameh M, Zihlif M, Feinfeld DA, Carvounis CP. Life-threatening hyperkalemia after intravenous labetolol injection for hypertensive emergency in a hemodialysis patient. Am J Nephrol 2001; 21: 241-244
55. Hassan H, Bastani B, Gellens M. Successful treatment of normeperidine neurotoxicity by hemodialysis. Am J Kidney Dis 2000; 35: 146-149
56. Haviv YS. Association of anticardiolipin antibodies with vascular access occlusion in hemodialysis patients: cause or effect? Nephron 2000; 86: 447-454
57. Head-Rapson AG, Devlin JC, Parker CJ, Hunter JM. Pharmacokinetics and pharmacodynamics of the three isomers of mivacurium in health, in end-stage renal failure and in patients with impaired renal function. Br J Anaesth 1995; 75: 31-36
58. Howell SJ, Sear YM, Yeates D, Goldacre M, Sear JW, Foex P. Risk factors for cardiovascular death after elective surgery under general anaesthesia. Br J Anaesth 1998; 80: 14-19
59. Howell SJ, Sear JW, Sear YM, Yeates D, Goldacre M, Foex P. Risk factors for cardiovascular death within 30 days after anaesthesia and urgent or emergency surgery: a nested case-control study. Br J Anaesth 1999; 82: 679-684
60. Ickx B, Cockshott ID, Barvais L, et al. Propofol infusion for induction and maintenance of anaesthesia in patients with endstage renal disease. Br J Anaesth 1998; 81: 854-860
61. Isbir CS, Akgun S, Yilmaz H, et al. Is there a role of angiotensinconverting enzyme gene polymorphism in the failure of arteriovenous femoral shunts for hemodialysis? Ann Vasc Surg 2001; 15: 443-446
62. Jassal SV, Coulshed SJ, Douglas JF, Stout RW. Autonomic neuropathy predisposing to arrhythmias in hemodialysis patients. Am J Kidney Dis 1997; 30: 219-223
63. Joint Specialty Committee on Renal Medicine of the Royal College of Physicians of London and the Renal Association, and the Royal College of General Practitioners. Chronic Kidney Disease in Adults: UK Guidelines for Identification, Management and Referral. London: Royal College of Physicians, 2006
64. Kirvela M, Lindgren L, Seppala T, Olkkola KT. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth 1996; 8: 13-18
65. Koehntop DE, Rodman JH. Fentanyl pharmacokinetics in patients undergoing renal transplantation. Pharmacotherapy 1997; 17: 746-752
66. Kurata C, Uehara A, Sugi T, et al. Cardiac autonomic neuropathy in patients with chronic renal failure on hemodialysis. Nephron 2000; 84: 312-319
67. Kurth T, Glynn RJ, Walker AM, et al. Analgesic use and change in kidney function in apparently healthy men. Am J Kidney Dis 2003; 42: 234-244
68. Launay-Vacher V, Karie S, Fau JB, Izzedine H, Deray G. Treatment of pain in patients with renal insufficiency: the World Health Organization three-step ladder adapted. J Pain 2005; 6: 137-148
69. Leblond FA, Giroux L, Villeneuve JP, Pichette V. Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Dispos 2000; 28: 1317-1320
70. Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999; 100: 1043-1049
71. Leman RB, Kratz JM, Gazes PC. Permanent cardiac pacing in patients on chronic renal dialysis. Am Heart J 1985; 110: 1242-1244
72. Lepage JY, Malinge M, Cozian A, Pinaud M, Blanloeil Y, Souron R. Vecuronium and atracurium in patients with end-stage renal failure. A comparative study. Br J Anaesth 1987; 59: 1004-1010
73. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classi- fication of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089-2100
74. Ligtenberg G, Blankestijn PJ, Oey PL, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340: 1321-1328
75. Litz RJ, Hubler M, Lorenz W, Meier VK, Albrecht DM. Renal responses to desflurane and isoflurane in patients with renal insufficiency. Anesthesiology 2002; 97: 1133-1136
76. Locatelli F, Bommer J, London GM, et al. Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment. Nephrol Dial Transplant 2001; 16: 459-468
77. London GM. Cardiovascular disease in chronic renal failure: pathophysiologic aspects. Semin Dial 2003; 16: 85-94
78. Lynam DP, Cronnelly R, Castagnoli KP, et al. The pharmacodynamics and pharmacokinetics of vecuronium in patients anesthetized with isoflurane with normal renal function or with renal failure. Anesthesiology 1988; 69: 227-231
79. Macdonald J, Marcora S, Jibani M, et al. GFR estimation using cystatin C is not independent of body composition. Am J Kidney Dis 2006; 48: 712-719
80. Manjunath G, Sarnak MJ, Levey AS. Estimating the glomerular filtration rate. Dos and don'ts for assessing kidney function. Postgrad Med 2001; 110: 55-62
81. Manns BJ, Burgess ED, Parsons HG, Schaefer JP, Hyndman ME, Scott-Douglas NW. Hyperhomocysteinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients. Kidney Int 1999; 55: 315-320
82. Massry SG. Is parathyroid hormone a uremic toxin? Nephron 1977; 19: 125-130
83. Matzke GR, Chan GL, Abraham PA. Codeine dosage in renal failure. Clin Pharm 1986; 5: 15-16
84. Mazze RI, Callan CM, Galvez ST, Delgado-Herrera L, Mayer DB. The effects of sevoflurane on serum creatinine and blood urea nitrogen concentrations: a retrospective, twenty-two-center, comparative evaluation of renal function in adult surgical patients. Anesth Analg 2000; 90: 683-688
85. Mazze RI, Calverley RK, Smith NT. Inorganic fluoride nephrotoxicity: prolonged enflurane and halothane anesthesia in volunteers. Anesthesiology 1977; 46: 265-271
86. McCauley J, Murray J, Jordan M, Scantlebury V, Vivas C, Shapiro R. Labetalol-induced hyperkalemia in renal transplant recipients. Am J Nephrol 2002; 22: 347-351
87. McLeod K, Watson MJ, Rawlins MD. Pharmacokinetics of pancuronium in patients with normal and impaired renal function. Br J Anaesth 1976; 48: 341-345
88. McNamara PJ, Slaughter RL, Pieper JA, Wyman MG, Lalka D. Factors influencing serum protein binding of lidocaine in humans. Anesth Analg 1981; 60: 395-400
89. Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005; 365: 331-340
90. Melendez JA, Delphin E, Lamb J, Rose E. Noncardiac surgery in heart transplant recipients in the cyclosporine era. J Cardiothorac Vasc Anesth 1991; 5: 218-220
91. Mirakhur RK. Safety aspects of non-depolarizing neuromuscular blocking agents with special reference to rocuronium bromide. Eur J Anaesthesiol Suppl 1994; 9: 133-140
92. Molino D, De Lucia D, Marotta R, et al. In uremia, plasma levels of anti-protein C and anti-protein S antibodies are associated with thrombosis. Kidney Int 2005; 68: 1223-1229
93. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. J Am Med Assoc 2001; 286: 954-959
94. Murphy EJ. Acute pain management pharmacology for the patient with concurrent renal or hepatic disease. Anaesth Intensive Care 2005; 33: 311-322
95. Naguib M. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth Analg 2007; 104: 575-581
96. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117-124
97. Nancarrow C, Runciman WB, Mather LE, Upton RN, Plummer JL. The influence of acidosis on the distribution of lidocaine and bupivacaine into the myocardium and brain of the sheep. Anesth Analg 1987; 66: 925-935
98. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 1999; 16: 9-13
99. Nishiyama T, Aibiki M, Hanaoka K. Inorganic fluoride kinetics and renal tubular function after sevoflurane anesthesia in chronic renal failure patients receiving hemodialysis. Anesth Analg 1996; 83: 574-577
100. NKF K/DOQI Guidelines, Clinical Practice Guidelines For Vascular Access. Available from http://www.kidney.org/professionals/kdoqi/ guideline-upHD-PD-VA/ va-intro.htm
101. Nolin TD, Frye RF, Matzke GR. Hepatic drug metabolism and transport in patients with kidney disease. Am J Kidney Dis 2003; 42: 906-925
102. Novis BK, Roizen MF, Aronson S, Thisted RA. Association of preoperative risk factors with postoperative acute renal failure. Anesth Analg 1994; 78: 143-149
103. Obrador GT, Pereira BJ. Systemic complications of chronic kidney disease. Pinpointing clinical manifestations and best management. Postgrad Med 2002; 111: 115-122
104. Palevsky PM. Perioperative management of patients with chronic kidney disease or ESRD. Best Pract Res Clin Anaesthesiol 2004; 18: 129-144
105. Parekh N. Hyperchloremic acidosis. Anesth Analg 2002; 95: 1821-1822
106. Pecoits-Filho R, Goncalves S, Barberato SH, et al. Impact of residual renal function on volume status in chronic renal failure. Blood Purif 2004; 22: 285-292
107. Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med 2000; 109: 307-314
108. Phillips BJ, Hunter JM. Use of mivacurium chloride by constant infusion in the anephric patient. Br J Anaesth 1992; 68: 492-498
109. Pivalizza EG, Abramson DC, Harvey A. Perioperative hypercoagulability in uremic patients: a viscoelastic study. J Clin Anesth 1997; 9: 442-445
110. Polkinghorne KR, McDonald SP, Atkins RC, Kerr PG. Vascular access and all-cause mortality: a propensity score analysis. J Am Soc Nephrol 2004; 15: 477-486
111. Rabelink TJ, Zwaginga JJ, Koomans HA, Sixma JJ. Thrombosis and hemostasis in renal disease. Kidney Int 1994; 46: 287-296
112. Raine AE. Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy. Lancet 1988; 1: 97-100
113. Robertson EN, Driessen JJ, Booij LH. Pharmacokinetics and pharmacodynamics of rocuronium in patients with and without renal failure. Eur J Anaesthesiol 2005; 22: 4-10
114. Roderick P, Willis NS, Blakeley S, Jones C, Tomson C. Correction of chronic metabolic acidosis for chronic kidney disease patients. Cochrane Database Syst Rev 2007; CD001890
115. Rokaw MD, West ME, Palevsky PM, Johnson JP. FK-506 and rapamycin but not cyclosporin inhibit aldosterone-stimulated sodium transport in A6 cells. Am J Physiol 1996; 271: C194-202
116. Sagripanti A, Cupisti A, Baicchi U, Ferdeghini M, Morelli E, Barsotti G. Plasma parameters of the prothrombotic state in chronic uremia. Nephron 1993; 63: 273-278
117. Sahin M, Kayatas M, Urun Y, Sennaroglu E, Akdur S. Performing only one cardiovascular reflex test has a high positive predictive value for diagnosing autonomic neuropathy in patients with chronic renal failure on hemodialysis. Ren Fail 2006; 28: 383-387
118. Sanya EO, Ogunniyi A. Cardiovascular autonomic neuropathy in non-diabetic Nigerian patients with chronic renal failure. West Afr J Med 2004; 23: 15-20
119. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116: 85-97
120. Schortgen F, Lacherade JC, Bruneel F, et al. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 2001; 357: 911-916
121. Schwab SJ, Quarles LD, Middleton JP, Cohan RH, Saeed M, Dennis VW. Hemodialysis-associated subclavian vein stenosis. Kidney Int 1988; 33: 1156-1159
122. Sear JW. Drug handling in renal impairment. Curr Anaesth Crit Care 1992; 3: 133-139
123. Sear JW, Hand CW, Moore RA, McQuay HJ. Studies on morphine disposition: influence of renal failure on the kinetics of morphine and its metabolites. Br J Anaesth 1989; 62: 28-32
124. Shahlaie K, Fox A, Butani L, Boggan JE. Spontaneous epidural hemorrhage in chronic renal failure. A case report and review. Pediatr Nephrol 2004; 19: 1168-1172
125. Sharrock NE, Beksac B, Flynn E, Go G, Della Valle AG. Hypotensive epidural anaesthesia in patients with preoperative renal dysfunction undergoing total hip replacement. Br J Anaesth 2006; 96: 207-212
126. Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985; 28: 830-838
127. Shemin D, Bostom AG, Laliberty P, Dworkin LD. Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis 2001; 38: 85-90
128. Sidi A, Kaplan RF, Davis RF. Prolonged neuromuscular blockade and ventilatory failure after renal transplantation and cyclosporine. Can J Anaesth 1990; 37: 543-548
129. Sladen RN, Endo E, Harrison T. Two-hour versus 22-hour creatinine clearance in critically ill patients. Anesthesiology 1987; 67: 1013-1016
130. Song IS, Yang WS, Kim SB, Lee JH, Kwon TW, Park JS. Association of plasma fibrinogen concentration with vascular access failure in hemodialysis patients. Nephrol Dial Transplant 1999; 14: 137-141
131. Sorgenfrei IF, Norrild K, Larsen PB, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology 2006; 104: 667-674
132. Spallone V, Mazzaferro S, Tomei E, et al. Autonomic neuropathy and secondary hyperparathyroidism in uraemia. Nephrol Dial Transplant 1990; 5: 128-130
133. Thapa S, Brull SJ. Succinylcholine-induced hyperkalemia in patients with renal failure: an old question revisited. Anesth Analg 2000; 91: 237-241
134. Toivonen HJ. Anaesthesia for patients with a transplanted organ. Acta Anaesthesiol Scand 2000; 44: 812-833
135. Tomura S, Nakamura Y, Deguchi F, Ando R, Chida Y, Marumo F. Coagulation and fibrinolysis in patients with chronic renal failure undergoing conservative treatment. Thromb Res 1991; 64: 81-90
136. Turney JH, Woods HF, Fewell MR, Weston MJ. Factor VIII complex in uraemia and effects of haemodialysis. Br Med J (Clin Res Ed) 1981; 282: 1653-1656
137. US Renal Data System. USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2007
138. Van Peer A, Vercauteren M, Noorduin H, Woestenborghs R, Heykants J. Alfentanil kinetics in renal insufficiency. Eur J Clin Pharmacol 1986; 30: 245-247
139. Vanacker BF, Vermeyen KM, Struys MM, et al. Reversal of rocuronium-induced neuromuscular block with the novel drug sugammadex is equally effective under maintenance anesthesia with propofol or sevoflurane. Anesth Analg 2007; 104: 563-568
140. Wallia R, Greenberg A, Piraino B, Mitro R, Puschett JB. Serum electrolyte patterns in end-stage renal disease. Am J Kidney Dis 1986; 8: 98-104
141. Ward S, Boheimer N, Weatherley BC, Simmonds RJ, Dopson TA. Pharmacokinetics of atracurium and its metabolites in patients with normal renal function, and in patients in renal failure. Br J Anaesth 1987; 59: 697-706
142. Webb MD. Type I second-degree AV block after neostigmine administration in a child with renal failure. Anesth Prog 1995; 42: 21-22
143. White C, Akbari A, Hussain N, et al. Chronic kidney disease stage in renal transplantation classification using cystatin C and creatinine-based equations. Nephrol Dial Transplant 2007; 22: 3013-3020
144. Wickstrom I. Enflurane anesthesia in living donor renal transplantation. Acta Anaesthesiol Scand 1981; 25: 263-269
145. Wierda JM, Kleef UW, Lambalk LM, Kloppenburg WD, Agoston S. The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. Can J Anaesth 1991; 38: 430-435
146. Wilcox CS. Regulation of renal blood flow by plasma chloride. J Clin Invest 1983; 71: 726-735 (Pubitemid 13160821)
147. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18: 139-185
148. Zaleski L, Abello D, Gold MI. Desflurane versus isoflurane in patients with chronic hepatic and renal disease. Anesth Analg 1993; 76: 353-356
149. Zand MS. Immunosuppression and immune monitoring after renal transplantation. Semin Dial 2005; 18: 511-519